Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120

AIDS

Volumn 12, Issue 12, 1998, Pages 1413-1418

  Fontenot, J Darrell ^a   Tan, Xin ^a   Phillips, David M ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

Antibody complementarity determining region; Antivirals; CD4 binding domain; HIV 1; Human mucin MUC1

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANTIGEN RECOGNITION; ARTICLE; COMPLEMENTARITY DETERMINING REGION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEXUAL TRANSMISSION; TANDEM REPEAT; VIRUS CELL INTERACTION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; ANTIGENS, CD4; BINDING SITES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MUCINS; NEUTRALIZATION TESTS; PEPTIDES; TANDEM REPEAT SEQUENCES;

EID: 0032552082     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199812000-00002     Document Type: Article

References (25)

1. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
3. Fontenot JD, Zacharopoulos VR, Phillips DM: Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles. J Virol 1996, 70:6557-6562.
4. Clothia C, Lesk AM, Tramontano A, et al.: Conformation of immunoglobulin hypervariable regions. Nature 1989, 342:877-883.
5. Wilson IA, Stanfield RL: Antibody-antigen interactions. Curr Opin Struct Biol 1993, 3:113-118.
6. Fontenot JD, Gatewood JM, Mariappan SVS, et al.: Human immunodeficiency virus (HIV) antigens: structure and serology of multivalent human mucin MUC1-HIV V3 chimeric proteins. Proc Natl Acad Sci USA 1995, 92:315-319.
7. Fontenot JD, Mariappan SVS, Catasti P, Domenech N, Finn OJ, Gupta G: Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope. J Biomol Struct Dyn 1995, 13:245-260.
8. Catasti P, Fontenot JD, Bradbury EM, Gupta G: Local and global structural properties of the HIV-MN V3 loop. J Biol Chem 1995, 270:2224-2232.
9. Fontenot JD, Vancott TC, Parekh BS, et al.: Presentation of HIV V3-loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential. AIDS 1995, 9:1121-1129.
10. Barbas C, Bjorling E, Chiodi F, et al.: Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 1992, 89:9339-9343.
11. Moore JP, McCutchan FE, Poon S-W, et al.: Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol 1994, 68:8350-8364.
12. Fontenot JD, Finn OJ, Dales N, Andrews PC, Montelaro RC: Synthesis of large multideterminant peptide immunogens using a poly-proline β-turn helix motif. Peptide Res 1993, 6:330-336.
13. Tan X, Phillips DM: Cell-mediated infection of cervix derived epithelial cells with primary isolates of human immunodeficiency virus. Arch Virol 1996, 141:1177-1189.
14. Burton DR, Pyati J, Koduri R, et al.: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
15. Chou PY, Fasman GD: Empirical predictions of protein conformation. Annu Rev Biochem 1978, 47:251-276.
16. Levi M, Sallberg M, Ruden U, et al.: A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc Natl Acad Sci USA 1993, 90:4374-4378.
17. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ: Humoral immunity against a tandem repeat epitope of human mucin muc-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 1994, 54:2856-2860.
18. Connor RI, Ho DD: Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol 1994, 68:4400-4408.
19. Barbas CF, Hu D, Dunlop N, et al.: In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity. Proc Natl Acad Sci U S A 1996, 91:3809-3813.
20. Javaherian K, Langlois AJ, McDanal C, et al.: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989, 86:6768-6772.
21. Olshevsky U, Helseth E, Furman C, Li J, Haseltine W, Sodroski J: Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol 1990, 64:5701-5707.
22. Ho DD, McKeating JA, Li XL, et al.: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991, 65:489-493.
23. Thali M, Furman C, Ho DD, et al.: Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 1992, 66:5635-5641.
24. Lasky LA, Nakamura C, Smith DH, et al.: Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987, 50:975-985.
25. Elias CJ, Heise LL: Challenges for the development of female-controlled vaginal microbicides. AIDS 1994, 8:1-9.